Smart speakers expected to penetrate healthcare without disrupting it very much

Artificially intelligent personal digital assistants controlled by voice à la Amazon Echo and Google Home have a bright future in healthcare. However, they will neither threaten health workers’ jobs nor draw strict regulatory action despite persistent concerns over privacy and security.

Such are the prime predictions of an international panel of up to 35 subject experts and industry stakeholders recruited to collaboratively consider various future scenarios and arrive at a consensus on the likelihood of each.

The panelists represented voice-technology developers, clinicians, and representatives of academia, governmental health agencies and nonprofit health associations. All had familiarity with the technology.

The virtual group had strong consensus on a scenario describing the use of voice-controlled intelligent personal assistants (VIPAs) for supporting elderly people, especially in situations requiring them to recall personal medical history.

Other applications in this same scenario included tech-supplied information, guided self-therapy and communication with healthcare professionals.

The study was conducted at the University of Potsdam in Germany and published April 9 in the Journal of Medical Internet Research.

“Although conversational assistants are not expected to replace medical workers, their use as operational supporting tools for healthcare professionals has strong potential in the industry,” write study authors Alena Ermolina, MSc, and Victor Tiberius, MBA. “To be able to meet consumer expectations and withstand competition within the next five years, healthcare companies are advised to carefully observe current research and development activities in the field of conversational artificial intelligence and allocate resources to optimize business processes using VIPAs.”

The study is posted in full for free.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.